LIVIVO - Search results -

Search results

Result 1 - 10 of total 163

Search options

Book: Antiretroviral resistance in clinical practice

Geretti, Anna Maria

2006

Author's details	ed. by Anna Maria Geretti
Keywords	HIV Infections / drug therapy ; Microbial Sensitivity Tests ; Anti-HIV Agents / pharmacology ; Drug Resistance, Viral ; HIV-1 / drug effects
Language	English
Size	VIII, 178 S. : Ill., graph. Darst.
Publisher	Mediscript
Publishing place	London
Publishing country	Great Britain
Document type	Book
HBZ-ID	HT015010113
ISBN	0-9551669-0-X ; 978-0-9551669-0-7
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2007 A 4290	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection.

Ferrari, Ludovica / Ruggiero, Alessandra / Stefani, Chiara / Benedetti, Livia / Piermatteo, Lorenzo / Andreassi, Eleonora / Caldara, Federica / Zace, Drieda / Pagliari, Matteo / Ceccherini-Silberstein, Francesca / Jones, Christopher / Iannetta, Marco / Geretti, Anna Maria

Scientific reports

2024 Volume 14, Issue 1, Page(s) 8337

Abstract: Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including ... ...

Abstract	Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population.
MeSH term(s)	Adult ; Animals ; Humans ; SARS-CoV-2 ; BNT162 Vaccine ; COVID-19 Vaccines/adverse effects ; HIV Infections ; COVID-19/prevention & control ; Immunoassay ; Antibodies ; Spiders ; Vaccination ; Antibodies, Viral ; Antibodies, Neutralizing
Chemical Substances	BNT162 Vaccine ; COVID-19 Vaccines ; Antibodies ; Antibodies, Viral ; Antibodies, Neutralizing
Language	English
Publishing date	2024-04-09
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-58597-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi.

Stockdale, Alexander J / Silungwe, Niza M / Shawa, Isaac Thom / Kreuels, Benno / Gordon, Melita A / Geretti, Anna Maria

BMC infectious diseases

2021 Volume 21, Issue 1, Page(s) 487

Abstract: Background: The World Health Organization (WHO) has targeted a reduction in viral hepatitis-related mortality by 65% and incidence by 90% by 2030, necessitating enhanced hepatitis B treatment and prevention programmes in low- and middle-income countries. ...

Abstract	Background: The World Health Organization (WHO) has targeted a reduction in viral hepatitis-related mortality by 65% and incidence by 90% by 2030, necessitating enhanced hepatitis B treatment and prevention programmes in low- and middle-income countries. Hepatitis B e antigen (HBeAg) status is used in the assessment of eligibility for antiviral treatment and for prevention of mother-to-child transmission (PMTCT). Accordingly, the WHO has classified HBeAg rapid diagnostic tests (RDTs) as essential medical devices. Methods: We assessed the performance characteristics of three commercially available HBeAg RDTs (SD Bioline, Alere, South Africa; Creative Diagnostics, USA; and Biopanda Reagents, UK) in two hepatitis B surface antigen-positive cohorts in Blantyre, Malawi: participants of a community study (n = 100) and hospitalised patients with cirrhosis or hepatocellular carcinoma (n = 94). Two investigators, blinded to the reference test result, independently assessed each assay. We used an enzyme-linked immunoassay (Monolisa HBeAg, Bio-Rad, France) as a reference test and quantified HBeAg concentration using dilutions of the WHO HBeAg standard. We related the findings to HBV DNA levels, and evaluated treatment eligibility using the TREAT-B score. Results: Among 194 HBsAg positive patients, median age was 37 years, 42% were femaleand 26% were HIV co-infected. HBeAg prevalence was 47/194 (24%). The three RDTs showed diagnostic sensitivity of 28% (95% CI 16-43), 53% (38-68) and 72% (57-84) and specificity of 96-100% for detection of HBeAg. Overall inter-rater agreement κ statistic was high at 0.9-1.0. Sensitivity for identifying patients at the threshold where antiviral treatment is recommended for PMTCT, with HBV DNA > 200,000 IU/ml (39/194; 20%), was 22, 49 and 54% respectively. Using the RDTs in place of the reference HBeAg assay resulted in 3/43 (9%), 5/43 (12%) and 8/43 (19%) of patients meeting the TREAT-B treatment criteria being misclassified as ineligible for treatment. A relationship between HBeAg concentration and HBeAg detection by RDT was observed. A minimum HBeAg concentration of 2.2-3.1 log Conclusions: Commercially available HBeAg RDTs lack sufficient sensitivity to accurately classify hepatitis B patients in Malawi. This has implications for hepatitis B public health programs in sub-Saharan Africa. Alternative diagnostic assays are recommended.
MeSH term(s)	Adult ; Antiviral Agents/therapeutic use ; Coinfection/virology ; DNA, Viral/analysis ; Diagnostic Tests, Routine/methods ; Enzyme-Linked Immunosorbent Assay/methods ; HIV Infections/complications ; Hepatitis B/complications ; Hepatitis B/diagnosis ; Hepatitis B Surface Antigens/analysis ; Hepatitis B e Antigens/blood ; Hepatitis B virus/immunology ; Hepatitis B virus/isolation & purification ; Humans ; Infectious Disease Transmission, Vertical/prevention & control ; Malawi ; Male ; Middle Aged ; Sensitivity and Specificity ; Serologic Tests
Chemical Substances	Antiviral Agents ; DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens
Language	English
Publishing date	2021-05-27
Publishing country	England
Document type	Journal Article
ISSN	1471-2334
ISSN (online)	1471-2334
DOI	10.1186/s12879-021-06134-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Genital herpes.

Geretti, A M

Sexually transmitted infections

2006 Volume 82 Suppl 4, Page(s) iv31–4

MeSH term(s)	Cell Culture Techniques ; DNA, Viral/analysis ; Female ; Herpes Genitalis/diagnosis ; Herpes Genitalis/virology ; Herpesvirus 1, Human/isolation & purification ; Herpesvirus 2, Human/isolation & purification ; Humans ; Immunoassay/methods ; Immunoassay/standards ; Male ; Mass Screening/methods ; Polymerase Chain Reaction/methods ; Polymerase Chain Reaction/standards ; Risk Factors ; Secondary Prevention ; Sensitivity and Specificity ; Vaginal Smears/standards
Chemical Substances	DNA, Viral
Language	English
Publishing date	2006-12
Publishing country	England
Document type	Journal Article ; Practice Guideline
ZDB-ID	1420303-0
ISSN	1472-3263 ; 1368-4973
ISSN (online)	1472-3263
ISSN	1368-4973
DOI	10.1136/sti.2006.023200
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi, Adam / Fopoussi, Olga Mafotsing / Torimiro, Judith / Atkins, Mark / Kouanfack, Charles / Geretti, Anna Maria

Open forum infectious diseases

2019 Volume 6, Issue 4, Page(s) ofz142

Abstract: This corrects the article DOI: 10.1093/ofid/ofy251.]. ...

Abstract	[This corrects the article DOI: 10.1093/ofid/ofy251.].
Language	English
Publishing date	2019-04-03
Publishing country	United States
Document type	Journal Article ; Published Erratum
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofz142
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe.

Rossetti, Barbara / Fabbiani, Massimiliano / Di Carlo, Domenico / Incardona, Francesca / Abecasis, Ana / Gomes, Perpetua / Geretti, Anna Maria / Seguin-Devaux, Carole / Garcia, Federico / Kaiser, Rolf / Modica, Sara / Shallvari, Adrian / Sönnerborg, Anders / Zazzi, Maurizio

HIV medicine

2022 Volume 23, Issue 7, Page(s) 774–789

Abstract: Objectives: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects.: Methods: Treatment-experienced individuals starting an INSTI-based regimen during 2012-2019 were selected ... ...

Abstract	Objectives: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects. Methods: Treatment-experienced individuals starting an INSTI-based regimen during 2012-2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) ≥ 1000 copies/mL or two ≥ 50 copies/ml or one VL measurement ≥ 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated. Results: Of 13 560 treatments analysed, 4284 were from INSTI-naïve, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naïve, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5-3.8] in IN-NV, 18.4% (95% CI: 15.8-21.2) in IN-V, 4.2% (95% CI: 3.6-4.9) in IE-NV and 23.9% (95% CI: 20.9-26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1-13.0) in IN-NV, 19.6% (95% CI: 17.5-21.6) in IN-V, 10.8% (95% CI: 10.0-11.6) in IE-NV and 21.7% (95% CI: 19.7-23.5) in IE-V subjects. Conclusions: Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure.
MeSH term(s)	Drug Resistance, Viral ; Europe ; HIV Infections/drug therapy ; HIV Integrase/genetics ; HIV Integrase Inhibitors/pharmacology ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Integrases/therapeutic use ; Oxazines/therapeutic use ; Viral Load
Chemical Substances	HIV Integrase Inhibitors ; Heterocyclic Compounds, 3-Ring ; Oxazines ; HIV Integrase (EC 2.7.7.-) ; Integrases (EC 2.7.7.-)
Language	English
Publishing date	2022-02-24
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2001932-4
ISSN	1468-1293 ; 1464-2662
ISSN (online)	1468-1293
ISSN	1464-2662
DOI	10.1111/hiv.13262
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5441: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection.

Villa, Giovanni / Owusu, Dorcas / Smith, Colette / Azumah, Marilyn / Abdullahi, Adam / Phillips, Suzannah / Sayeed, Laila / Austin, Harrison / Chadwick, David / Phillips, Richard Odame / Geretti, Anna Maria

Hepatology communications

2022 Volume 6, Issue 11, Page(s) 3036–3051

Abstract: There is a heavy burden of liver disease in West Africa. While the role of hepatitis B virus (HBV) infection is well recognized, less is known about the contributing role of liver steatosis and how the two interact in the context of human ... ...

Abstract	There is a heavy burden of liver disease in West Africa. While the role of hepatitis B virus (HBV) infection is well recognized, less is known about the contributing role of liver steatosis and how the two interact in the context of human immunodeficiency virus (HIV) infection. Adults with HIV in Ghana underwent FibroScan measurements to determine prevalence of liver steatosis (expressed as controlled attenuation parameter [CAP]) and fibrosis (expressed as liver stiffness [LS]). We explored contributing factors in linear regression models, including demographics, lifestyle characteristics, medical history, HIV and HBV status, and measurements of metabolic syndrome. Among 329 adults (72.3% women; median age, 47 years), 322 (97.9%) were on antiretroviral therapy (median duration, 8.9 years). CD4 counts were preserved (median, 619 cells/mm
MeSH term(s)	Adult ; Male ; Female ; Humans ; Middle Aged ; Coinfection/epidemiology ; Hepatitis B virus/genetics ; Stavudine ; Metabolic Syndrome/epidemiology ; Liver Cirrhosis/diagnostic imaging ; HIV Infections/complications ; Fatty Liver/diagnostic imaging ; Hepatitis B/complications ; HIV/genetics ; RNA ; Ghana/epidemiology
Chemical Substances	Stavudine (BO9LE4QFZF) ; RNA (63231-63-0)
Language	English
Publishing date	2022-09-14
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2471-254X
ISSN (online)	2471-254X
DOI	10.1002/hep4.2000
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi.

Stockdale, Alexander J / Meiring, James E / Shawa, Isaac T / Thindwa, Deus / Silungwe, Niza M / Mbewe, Maurice / Kachala, Rabson / Kreuels, Benno / Patel, Pratiksha / Patel, Priyanka / Henrion, Marc Y R / Bar-Zeev, Naor / Swarthout, Todd D / Heyderman, Robert S / Gordon, Stephen B / Maria Geretti, Anna / Gordon, Melita A

The Journal of infectious diseases

2022 Volume 226, Issue 5, Page(s) 871–880

Abstract: Background: Hepatitis B is the leading cause of cirrhosis and liver cancer in sub-Saharan Africa. To reduce mortality, antiviral treatment programs are needed. We estimated prevalence, vaccine impact, and need for antiviral treatment in Blantyre, Malawi. ...

Abstract	Background: Hepatitis B is the leading cause of cirrhosis and liver cancer in sub-Saharan Africa. To reduce mortality, antiviral treatment programs are needed. We estimated prevalence, vaccine impact, and need for antiviral treatment in Blantyre, Malawi. Methods: We conducted a household study in 2016-2018. We selected individuals from a census using random sampling and estimated age-sex-standardized hepatitis B surface antigen (HBsAg) seroprevalence. Impact of infant hepatitis B vaccination was estimated by binomial log-linear regression comparing individuals born before and after vaccine implementation. In HBsAg-positive adults, eligibility for antiviral therapy was assessed. Results: Of 97386 censused individuals, 6073 (median age 18 years; 56.7% female) were sampled. HBsAg seroprevalence was 5.1% (95% confidence interval [CI], 4.3%-6.1%) among adults and 0.3% (95% CI, .1%-.6%) among children born after vaccine introduction. Estimated vaccine impact was 95.8% (95% CI, 70.3%-99.4%). Of HBsAg-positive adults, 26% were HIV-positive. Among HIV-negative individuals, 3%, 6%, and 9% were eligible for hepatitis B treatment by WHO, European, and American hepatology association criteria, respectively. Conclusions: Infant HBV vaccination has been highly effective in reducing HBsAg prevalence in urban Malawi. Up to 9% of HBsAg-positive HIV-negative adults are eligible, but have an unmet need, for antiviral therapy.
MeSH term(s)	Adolescent ; Adult ; Antiviral Agents/therapeutic use ; Child ; Female ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Hepatitis B/drug therapy ; Hepatitis B/epidemiology ; Hepatitis B/prevention & control ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines/therapeutic use ; Hepatitis B virus ; Humans ; Infant ; Malawi/epidemiology ; Male ; Seroepidemiologic Studies ; Vaccination
Chemical Substances	Antiviral Agents ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines
Language	English
Publishing date	2022-09-26
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiab562
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.50: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi, Adam / Fopoussi, Olga Mafotsing / Torimiro, Judith / Atkins, Mark / Kouanfack, Charles / Geretti, Anna Maria

Open forum infectious diseases

2018 Volume 5, Issue 10, Page(s) ofy251

Abstract: Background: We monitored the evolution of markers of hepatitis B virus (HBV) infection in virologically suppressed HIV-positive patients switching to nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy within a randomized ... ...

Abstract	Background: We monitored the evolution of markers of hepatitis B virus (HBV) infection in virologically suppressed HIV-positive patients switching to nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy within a randomized trial in Cameroon. Methods: Results: Participants (n = 80, 75% females) had a plasma HIV-1 RNA <60 copies/mL, a median CD4 count of 466 cells/mm Conclusions: Evolving treatment strategies for sub-Saharan Africa must be accompanied by the formulation and implementation of policy to guide appropriate assessment and management of HBV status.
Language	English
Publishing date	2018-10-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofy251
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pneumocystis

Kelly, Sophie / Waters, Laura / Cevik, Muge / Collins, Simon / Lewis, Joe / Wu, Meng-San / Blanchard, Tom J / Geretti, Anna M

Clinical medicine (London, England)

2020 Volume 20, Issue 6, Page(s) 590–592

Abstract: While clinical environments are highly focused on COVID-19, reports of missed or delayed treatment for conditions that imitate COVID-19, such as pneumonia caused by the ... ...

Abstract	While clinical environments are highly focused on COVID-19, reports of missed or delayed treatment for conditions that imitate COVID-19, such as pneumonia caused by the fungus
MeSH term(s)	AIDS-Related Opportunistic Infections/diagnosis ; AIDS-Related Opportunistic Infections/pathology ; AIDS-Related Opportunistic Infections/physiopathology ; AIDS-Related Opportunistic Infections/therapy ; COVID-19 ; Coronavirus Infections ; Diagnosis, Differential ; Fatal Outcome ; Humans ; Lung/diagnostic imaging ; Lung/pathology ; Male ; Middle Aged ; Pandemics ; Pneumocystis carinii ; Pneumonia, Pneumocystis/diagnosis ; Pneumonia, Pneumocystis/pathology ; Pneumonia, Pneumocystis/physiopathology ; Pneumonia, Pneumocystis/therapy ; Pneumonia, Viral
Keywords	covid19
Language	English
Publishing date	2020-11-13
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2048646-7
ISSN	1473-4893 ; 1470-2118
ISSN (online)	1473-4893
ISSN	1470-2118
DOI	10.7861/clinmed.2020-0565
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5439: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito